Side effects were recorded in a comparable proportion of 2 out of 13 patients (15%; P = 1.00) in the anti-TNF dose intensification group: One female UC patient had to stop ADL therapy because of a lupus-like syndrome, one male CD patient could continue intensified IFX medication despite mild anti-TNF-induced psoriasis that was treated with topical steroids. This evidence concerns the gene TNF and psoriasis.